The Patient Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
Activate Your Account with an access code or Create a New Account
Melinda L. Telli, M.D.
Medical oncologist, Breast specialist
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
- 900 Blake Wilbur Drive
- 1st Floor
- Palo Alto , CA 94304
- Phone: 650-498-6004
- 900 Blake Wilbur Drive
- 1st Floor
- Palo Alto , CA 94304
- Phone: 650-498-6004
- 900 Blake Wilbur Drive
- 1st Floor
- Palo Alto , CA 94304
- Phone: 650-498-6004
Practice Areas
Professional Education
- B.A., University of Pennsylvania, Biology, with Distinction (1996)
- M.D., George Washington University, Medicine, with Distinction (2002)
- Residency, Stanford University, Internal Medicine (2005)
- Fellowship, Stanford University, Medical Oncology (2008)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2005)
- Board Certification: Medical Oncology, American Board of Internal Medicine (2008)
- Board Certification, American Board of Internal Medicine, Internal Medicine (2015)
Honors & Awards
- Career Catalyst Research Award, Susan G. Komen for the Cure (2012)
- Champion Award, Triple Step Toward the Cure (2015)
- Fellowship Award, Susan G. Komen for the Cure (2008)
- Komen Leadership Award, Susan G. Komen for the Cure (2015)
- Merit Award, American Society of Clinical Oncology (2008)
- Nadia's Gift, Nadia's Gift Foundation (2015)
- New Investigator Award, Stanford Cancer Institute (2011)
- Oncology Division Teaching Award, Stanford University School of Medicine (2010, 2012, 2013, 2014)
- Young Investigator Award, American Society of Clinical Oncology (2009)
Administrative Appointments
- Breast Cancer Guidelines Panel, National Comprehensive Cancer Network (2014 - Present)
- Breast Cancer Maintenance of Certification Working Group, American Society of Clinical Oncology (2013 - 2014)
- Breast Oncology Protocol Review Committee Co-Chair, Stanford University (2015 - Present)
- Komen Scholar, Susan G. Komen for the Cure (2015 - Present)
- Medical Oncology SEP Committee, American Board of Internal Medicine (2014 - Present)
- Program Committee, ASCO Breast Cancer Symposium (2010 - 2013)
- Scientific Program Committee, Triple Negative Breast Cancer/Cytotoxics/Local Therapy, American Society of Clinical Oncology (2010 - 2013)
- Scientific Review Committee, Stanford Cancer Institute (2016 - Present)
Publications
-
Phyllodes tumors of the breast: natural history, diagnosis, and treatment.
Telli, M. L., Horst, K. C., Guardino, A. E., Dirbas, F. M., & Carlson, R. W. (2007). Phyllodes tumors of the breast: natural history, diagnosis, and treatment. Journal of the National Comprehensive Cancer Network , 5(3), 324–330. -
Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007). Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. JOURNAL OF CLINICAL ONCOLOGY, 25(23), 3525–3533. -
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613–1618. -
First-Line Chemotherapy for Metastatic Breast Cancer
Telli, M. L., & Carlson, R. W. (2009). First-Line Chemotherapy for Metastatic Breast Cancer. CLINICAL BREAST CANCER, 9, S66–S72.
-
Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls
Gramatges, M. M., Telli, M. L., Balise, R., & Ford, J. M. (2010). Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 19(2), 605–613.
-
Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California
Gomez, S. L., Lichtensztajn, D., Kurian, A. W., Telli, M. L., Chang, E. T., Keegan, T. H. M., … Clarke, C. A. (2010). Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California. JOURNAL OF CLINICAL ONCOLOGY, 28(10), E155–E157.
-
Novel Treatment Approaches for Triple-Negative Breast Cancer
Telli, M. L., & Ford, J. M. (2010). Novel Treatment Approaches for Triple-Negative Breast Cancer. CLINICAL BREAST CANCER, 10, E16–E22.
-
Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H. M., McClure, L. A., Lichtensztajn, D., … Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. BREAST CANCER RESEARCH AND TREATMENT, 127(2), 471–478.
-
Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally?
Yoon, G. J., Telli, M. L., Kao, D. P., Matsuda, K. Y., Carlson, R. W., & Witteles, R. M. (2010). Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally? JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 56(20), 1644–1650.
-
PARP inhibitors in breast cancer.
Telli, M. L., & Ford, J. M. (2010). PARP inhibitors in breast cancer. Clinical Advances in Hematology & Oncology : H&O, 8(9), 629–635.
-
Trastuzumab-Related Cardiac Dysfunction
Telli, M. L., & Witteles, R. M. (2011). Trastuzumab-Related Cardiac Dysfunction. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(2), 243–249.
-
Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?
Witteles, R. M., Fowler, M. B., & Telli, M. L. (2011). Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented? HEART FAILURE CLINICS, 7(3), 333-?
-
PARP inhibitors in cancer: moving beyond BRCA
Telli, M. L. (2011). PARP inhibitors in cancer: moving beyond BRCA. LANCET ONCOLOGY, 12(9), 827–828.
-
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort
Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., Balmana, J., … Garber, J. E. (2012). Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. BREAST CANCER RESEARCH AND TREATMENT, 133(3), 1125–1130.
-
Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
Witteles, R. M., & Telli, M. (2012). Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned? JOURNAL OF CLINICAL ONCOLOGY, 30(16), 1916–1918.
-
Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
Powell, A. A., Talasaz, A. A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., … Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).
-
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome
Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., Ganjoo, K., … Telli, M. L. (2012). Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 939–942.
-
Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer.
Palesh, O., Peppone, L., Innominato, P. F., Janelsins, M., Jeong, M., Sprod, L., … Mustian, K. (2012). Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nature and Science of Sleep, 4, 151–162.
-
Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells
Yang, L. J., Guo, Y. L., Trygankova, O., Li, Q. Y., Maloney, J. A., Steinhauer, M., & Williamson, J. R. (1999). Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells. BIOCHEMICAL PHARMACOLOGY, 57(4), 425–432.
-
Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. Journal of the American Medical Informatics Association , 20(6), 1059–66.
-
Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer
Telli, M. L. (2013). Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(29).
-
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, B., McPherson, L., … Kurian, A. W. (2013). A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. BREAST CANCER RESEARCH AND TREATMENT, electronic publication ahead of print, October 30.
-
Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer.
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer. AMIA Summits on Translational Science Proceedings AMIA Summit on Translational Science, 2013, 62-?
-
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
Zhang, H., Cohen, A. L., Krishnakumar, S., Wapnir, I. L., Veeriah, S., Deng, G., … Jeffrey, S. S. (2014). Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Research , 16(2), R36-?
-
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Deng, G., Krishnakumar, S., Powell, A. A., Zhang, H., Mindrinos, M. N., Telli, M. L., … Jeffrey, S. S. (2014). Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer, 14, 456-?
-
(18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru, A., Mosci, C., Shen, B., Chin, F. T., Mittra, E., Telli, M. L., & Gambhir, S. S. (2014). (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. Radiology, 273(2), 549–559.
-
Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
Telli, M. (2014). Optimizing chemotherapy in triple-negative breast cancer: the role of platinum. American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting, 34, e37–42.
-
The future of breast cancer systemic therapy: the next 10 years.
Telli, M. L., & Sledge, G. W. (2015). The future of breast cancer systemic therapy: the next 10 years. Journal of Molecular Medicine (Berlin, Germany), 93(2), 119–125.
-
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., … Ford, J. M. (2015). Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Journal of Clinical Oncology , 33(17), 1895–1901.
-
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
Watkins, J., Weekes, D., Shah, V., Gazinska, P., Joshi, S., Sidhu, B., … Tutt, A. N. J. (2015). Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. CANCER DISCOVERY, 5(5), 488–505.
-
The role of platinum therapy in triple-negative breast cancer
Afghahi, A., & Telli, M. L. (2014). The role of platinum therapy in triple-negative breast cancer. Breast Cancer Management, 3(4).
-
Breast Cancer, Version 1.2016.
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2015). Breast Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network : JNCCN, 13(12), 1475–85.
-
Evolving treatment strategies for triple-negative breast cancer.
Telli, M. (2015). Evolving treatment strategies for triple-negative breast cancer. Journal of the National Comprehensive Cancer Network , 13(5), 652–654.
-
Breast Cancer Version 2.2015
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2015). Breast Cancer Version 2.2015. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(4), 448–475.
-
Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity
Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., … Wu, J. C. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. NATURE MEDICINE, 22(5), 547–556.
-
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline
Denduluri, N., Somerfield, M. R., Eisen, A., Holloway, J. N., Hurria, A., King, T. A., … Wolff, A. C. (2016). Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. JOURNAL OF CLINICAL ONCOLOGY, 34(20), 2416–U186.
-
Invasive Breast Cancer Version 1.2016 Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2016). Invasive Breast Cancer Version 1.2016 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(3), 324–354.
-
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., … Richardson, A. L. (2016). Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research , 22(15), 3764–3773.
-
Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
Tsai, J., Bertoni, D., Hernandez-Boussard, T., Telli, M. L., & Wapnir, I. L. (2016). Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer. Annals of Surgical Oncology, 23(10), 3310–3316.
-
Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.
Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., … Telli, M. L. (2016). Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. Journal of Oncology Practice / American Society of Clinical Oncology, 12(8), 763–764.
-
Breast Cancer After Hodgkin Lymphoma: The Price of Success.
Manzo, V., Dirbas, F., & Telli, M. L. (2016). Breast Cancer After Hodgkin Lymphoma: The Price of Success. Oncology (Williston Park, N.Y.), 30(12).
-
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Isakoff, S. J., Puhalla, S., Domchek, S. M., Friedlander, M., Kaufman, B., Robson, M., … Shepherd, S. P. (2016). A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology , -?
-
Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., … Telli, M. L. (2017). Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
-
Genetics of triple-negative breast cancer: Implications for patient care.
Afghahi, A., Telli, M. L., & Kurian, A. W. Genetics of triple-negative breast cancer: Implications for patient care. Current Problems in Cancer, 40(2-4), 130–140.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Patient Comments
Patients comments are gathered from our Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
SHC Patient, Apr 2017
Jessica Foran and Melinda Telli are superlative givers of care. I cannot express how positively they have both impacted my life during and post cancer treatment.
SHC Patient, Feb 2017
Dr. Telli was so thorough & professional. She took her time and answered all my questions. She was able to provide studies to reinforce her recommendations for my care.
SHC Patient, Feb 2017
I love the dr.!!!
SHC Patient, Jan 2017
Excellent care in explaining options that were easy to understand and explaining details and status of my prognosis.
SHC Patient, Jan 2017
Excellent physician!
SHC Patient, Jan 2017
Dr. Telli is professional, warm, and caring - an IDEAL care provider!
SHC Patient, Jan 2017
Have always had good experiences/contacts at this facility.
SHC Patient, Jan 2017
Dr. Telli, Josh and Pei-ter are a great and compassionate team.
SHC Patient, Dec 2016
Dr. Telli is the best physician - she explained - everything thoroughly and was very patient.
SHC Patient, Dec 2016
Dr. Telli provides reassurance and is very knowledgeable on treatment of breast cancer.
SHC Patient, Nov 2016
Dr. Telli is the most compassionate and kind doctor I have ever met.
SHC Patient, Oct 2016
Dr. Melinda Telli is a saint - no, really!!
SHC Patient, Oct 2016
They make me feel confident in asking about any concern I have.
SHC Patient, Oct 2016
Dr. Telli is a fantastic doctor. She has a very good bedside manner and very caring.
SHC Patient, Oct 2016
Love Dr. Telli!
SHC Patient, Oct 2016
Very caring, outstanding doctor.
SHC Patient, Sep 2016
Thanks to these doctors, this place and their care I'm still alive. Thank you.
SHC Patient, Sep 2016
I needed to discuss doctor's recommendation in more detail and to ask several significant questions. The follow-up by doctor after the appt. was poor.
SHC Patient, Aug 2016
Dr. Telli always provides a complete evaluation, not just related to the purpose of the visit. She is the perfect blend of the art and science of medicine.
SHC Patient, Aug 2016
Dr. Telli is great!
SHC Patient, Aug 2016
Explained things very clearly. Drew diagrams to explain.
SHC Patient, Jul 2016
Dr. Telli is a truly wonderful physician. She has genuine care and concern and we are very grateful to be in her care.
SHC Patient, Jul 2016
Dr. Telli is wonderful and her fellow is equally as talented.
SHC Patient, Jun 2016
Dr. Telli very compassionate & kind. Very thorough.
SHC Patient, Jun 2016
Dr. Telli is excellent, as are Greg (her intern) Larissa & Kiran. All very good at explaining my diagnosis, medications & what to expect!
SHC Patient, May 2016
Good.
SHC Patient, May 2016
Dr Telli and staff are wonderful. Well worth the drive from Reno!
SHC Patient, Apr 2016
Exceptionally high level of compassion; provided a very clear rationale for next steps in my medical care.
SHC Patient, Apr 2016
Dr. Telli is technically an excellent oncologist, but the human side of her approach puts her in a completely different class of other doctor's I've encountered. She is truly spectacular.
SHC Patient, Apr 2016
Dr. Telli and her associate spent a good deal of time w/ me in examination, analysis and preparation of a Tx. plan, and later in their explanations of this plan. I had a very good experience w/ Dr. Telli and her team.
SHC Patient, Apr 2016
Dr. Telli is professional, caring. Very happy to have her on my corner.
SHC Patient, Apr 2016
Dr. Telli and Larissa are the best. My husband felt so well informed & supported he said he wish that he had had a tape of the conversation.
SHC Patient, Apr 2016
Dr. Telli is by far the finest doc. I have ever dealt with as cared for by heaps of empathy and delightful person! I have considerable experience with Stanford across several disciplines - She is THE BEST.
SHC Patient, Mar 2016
I love Dr. Telli - she saved my life.
SHC Patient, Mar 2016
Dr. Telli is great. She also has a wonderful touch. We (my husband comes with) travel quite a ways to see her.
SHC Patient, Mar 2016
I have much confidence in Doctor Telli, Melinda because she doesn't leave me without treatment.
SHC Patient, Mar 2016
These "very good" are all true. Dr.Waprin & Dr.Telli & their staff were terrific.
SHC Patient, Mar 2016
Dr Telli is fantastic care provider. I highly recommend her and thankful to have her as my Oncologist after a long search.
SHC Patient, Feb 2016
Extremely informative & pleasant -
SHC Patient, Dec 2015
Dr. Telli excellent.
SHC Patient, Nov 2015
Both Dr. Telli and Dr. Afghahi are helpful and willing to discuss any questions I have. I am in a clinic trial with them but wish I were able to transfer all of my care. However, distant makes that impossible.
SHC Patient, Sep 2015
Dr. Telli is an amazing doctor!! I can't say enough good about her.
SHC Patient, Sep 2015
Wonderful experience.
SHC Patient, Aug 2015
This was the first time I had met Dr. Telli. I found her to be very knowledgeable, professional, caring, intelligent, clear and pleasant to deal with.
SHC Patient, Jul 2015
I feel comfortable and I have trust in Dr. Telli, which gives me peace of mind.
SHC Patient, Jul 2015
My team take very good care of me.
SHC Patient, Jun 2015
Extremely pleased with Dr. Telli & Stanford on the whole.
SHC Patient, May 2015
Dr. Telli is amazing. So professional, yet compassionate and encouraging.
SHC Patient, May 2015
Dr. Melinda Telli has just the right balance of intelligent, specific knowledge and the ability to convey it in terms we could understand. Great "bedside" manner. TOTALLY professional.
SHC Patient, May 2015
I always feel fully satisfied that I have been completely understood & given excellent treatment.
SHC Patient, Apr 2015
Excellent Dr. Telli is the BEST.
SHC Patient, Mar 2015
Dr. Telli is what every Dr. should be. She is wonderful.
SHC Patient, Feb 2015
Dr. Telli is an excellent care provider, very knowledgeable, up-to-date, caring, easy to understand.
SHC Patient, Oct 2014
She is my life line to emotional and health care.
SHC Patient, Oct 2014
Dr. Telli is very kind, informative and empathetic. She has an excellent bedside manner.
SHC Patient, Sep 2014
Dr. Telli should be cloned - all drs. should be her. She is wonderful!
SHC Patient, Aug 2014
Good experience.
SHC Patient, Aug 2014
Dr. Telli was wonderful. I came to her for a second opinion and she was much more helpful than my regular doctor.
SHC Patient, Aug 2014
Dr. Melinda Telli is exceptional. I would never go back to my previous oncologist. I totally trust her & think she's an outstanding doctor.
SHC Patient, Jun 2014
Dr. Telli is an amazing listener, a warm & engaging person, & solution-focused.
SHC Patient, Jun 2014
Dr. Telli made decision for treatment & explained why.
SHC Patient, May 2014
Dr. Telli spent quality time with me and covered all my concerns. I felt very comforted by her manner and knowledge.
SHC Patient, May 2014
My provider is great!! Always makes me feel I am HER main concern - And my total well being - Not just the cancer.
SHC Patient, May 2014
Dr. Telli is everything we hoped for & more.
SHC Patient, May 2014
I love Melinda Telli and all of her staff -- She is a very compassionate doctor & spends a great deal of time w/me.
SHC Patient, Feb 2014
Both the PA & Dr. Telli were very clean & helpful in explaining options to me.
SHC Patient, Jan 2014
Dr. Telli and her staff are the best!
SHC Patient, Jan 2014
Very good.
SHC Patient, Apr 2017
Jessica Foran and Melinda Telli are superlative givers of care. I cannot express how positively they have both impacted my life during and post cancer treatment.
SHC Patient, Feb 2017
Dr. Telli was so thorough & professional. She took her time and answered all my questions. She was able to provide studies to reinforce her recommendations for my care.
SHC Patient, Feb 2017
I love the dr.!!!
SHC Patient, Jan 2017
Excellent care in explaining options that were easy to understand and explaining details and status of my prognosis.
SHC Patient, Jan 2017
Excellent physician!
SHC Patient, Jan 2017
Dr. Telli is professional, warm, and caring - an IDEAL care provider!
SHC Patient, Jan 2017
Have always had good experiences/contacts at this facility.
SHC Patient, Jan 2017
Dr. Telli, Josh and Pei-ter are a great and compassionate team.
SHC Patient, Dec 2016
Dr. Telli is the best physician - she explained - everything thoroughly and was very patient.
SHC Patient, Dec 2016
Dr. Telli provides reassurance and is very knowledgeable on treatment of breast cancer.
SHC Patient, Nov 2016
Dr. Telli is the most compassionate and kind doctor I have ever met.
SHC Patient, Oct 2016
Dr. Melinda Telli is a saint - no, really!!
View All 68 Patient Comments »